599 related articles for article (PubMed ID: 15073863)
1. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
2. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
6. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
7. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
8. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
9. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
14. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
Comandone A; Passera R; Boglione A; Tagini V; Ferrari S; Cattel L
Acta Oncol; 2005; 44(4):406-11. PubMed ID: 16120550
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.
Fujita Y; Nakamura T; Aomori T; Nishiba H; Shinozaki H; Yanagawa T; Takagishi K; Watanabe H; Okada Y; Nakamura K; Horiuchi R; Yamamoto K
J Chemother; 2010 Jun; 22(3):186-90. PubMed ID: 20566424
[TBL] [Abstract][Full Text] [Related]
16. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
17. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
18. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas.
Delepine N; Delepine G; Jasmin C; Desbois JC; Cornille H; Mathé G
Biomed Pharmacother; 1988; 42(4):257-62. PubMed ID: 3191203
[TBL] [Abstract][Full Text] [Related]
19. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
